Antibodies specific for epidermal growth factor receptor variant III and their uses
The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.
1. An isolated antibody, which specifically binds to Epidermal Growth Factor Receptor Variant III (EGFRvIII), wherein the antibody comprises:
(a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising a sequence selected from the group consisting of SEQ ID NO: 62, 63, 64, 74, 75, 76, 80, 81, 82, 88, 89, 90, 93, 94, 95, 99, 100, 101, 109, 110, 111, 115, 116, 117, 121, 122, 123, 132, 133, 134, 137, 138, 139, 143, 144, and 145; (ii) a VH CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 65, 66, 68, 69, 70, 71, 77, 78, 83, 84, 86, 87, 91, 92, 96, 97, 98, 102, 103, 105, 106, 112, 113, 118, 119, 124, 125, 127, 128, 130, 131, 135, 136, 140, 141, 146, and 147; and (iii) a VH CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 67, 72, 73, 79, 85, 104, 107, 108, 114, 120, 126, 129, 142, and 148; and
(b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 149, 154, 156, 159, 162, 165, 166, 168, 169, 170, 171, 173, 174, 176, 178, 181, 182, 185, 187, 190, 192, 195, and 198; (ii) a VL CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 150, 152, 155, 157, 160, 163, 172, 175, 179, 183, 186, 188, 191, 193, 196, and 199; and (iii) a VL CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 151, 153, 158, 161, 164, 167, 177, 180, 184, 189, 194, 197, and 200.
2. An isolated antibody which specifically binds to Epidermal Growth Factor Receptor Variant III (EGFRvIII), wherein the antibody comprises:
a VH region comprising a VH sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44, 46, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 202, 203, 204, 205, 206, 207, 208, 209, 210, 214, 216, 217, and 218; and
a VL region comprising a VL sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, 51, 211, 212, 213, and 215.
3. The antibody of claim 1 , wherein the antibody comprises an acyl donor glutamine-containing tag engineered at a specific site.
4. A nucleic acid encoding the antibody of claim 1 .
5. A vector comprising the nucleic acid of claim 4 .
6. A host cell comprising the nucleic acid of claim 4 .
7. A conjugate of the antibody of claim 1 , wherein the antibody is conjugated to an agent, wherein the agent is selected from the group consisting of a cytotoxic agent, an immunomodulating agent, an imaging agent, a therapeutic protein, a biopolymer, and an oligonucleotide.
8. A pharmaceutical composition comprising the antibody of claim 1 .
9. A method of treating a condition associated with malignant cells expressing EGFRvIII in a subject comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 8 .
10. The method of claim 9 , wherein the condition is a cancer.
11. The method of claim 10 , wherein the cancer is an EGFRvIII related cancer selected from the group consisting of glioblastoma multiform, anaplastic astrocytoma, giant cell glioblastoma, gliosarcoma, anaplastic oligodendroglioma, anaplastic ependymoma, anaplastic oligoastrocytoma, choroid plexus carcinoma, anaplastic ganglioglioma, pineoblastoma, pineocytoma, meningioma, medulloepithelioma, ependymoblastoma, medulloblastoma, supraentorial primitive neuroectodermal tumor, atypical teratoid/rhabdoid tumor, mixed glioma, head and neck cancer, non-small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, medullobastoma, colorectal cancer, anal cancer, cervical cancer, renal cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, gastric cancer, thyroid cancer, mesothelioma, uterine cancer, lymphoma, and leukemia.
12. A method of inhibiting tumor growth or progression in a subject who has malignant cells expressing EGFRvIII, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 8 to the subject.
13. A method of inhibiting metastasis of malignant cells expressing EGFRvIII in a subject, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 8 to the subject.
14. A method of inducing tumor regression in a subject who has malignant cells expressing EGFRvIII, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 8 to the subject.
15. A method of producing an antibody, comprising culturing the host cell of claim 6 under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture.
16. The isolated antibody of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising a sequence selected from the group consisting of SEQ ID NO: 62, 63, and 64; (ii) a VH CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 65, 66, 68, 69, 70, and 71; and (iii) a VH CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 67, 72, and 73; and
(b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 149 and 154; (ii) a VL CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 150, 152, and 155; and (iii) a VL CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 151 and 153.
17. The isolated antibody of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising a sequence selected from the group consisting of SEQ ID NO: 74, 75, 76, 80, 81, 82, 88, 89, 90, 93, 94, 95, 99, 100, and 101, and 145; (ii) a VH CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 77, 78, 83, 84, 86, 87, 91, 92, 96, 97, 98, 102, 103, 105, and 106; and (iii) a VH CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 79, 85, 104, 107, and 108; and
(b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 156, 159, 162, 165, 166, 168, 169, 170, 171, 173, 174, 176, 178, and 181; (ii) a VL CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 157, 160, 163, and 172; and (iii) a VL CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 158, 161, 164, 167, 177, and 180.
18. The isolated antibody of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising a sequence selected from the group consisting of SEQ ID NO: 109, 110, 111, 115, 116, 117, 121, 122, 123, 132, 133, and 134; (ii) a VH CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 112, 113, 118, 119, 124, 125, 127, 128, 130, 131, 135, and 136; and (iii) a VH CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 114, 120, 126, and 129; and
(b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 182, 185, 187, 190, and 192; (ii) a VL CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 183, 186, 188, 191, and 193; and (iii) a VL CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 184, 189, and 194.
19. The isolated antibody of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising a sequence selected from the group consisting of SEQ ID NO: 137, 138, 139, 143, 144, and 145; (ii) a VH CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 140, 141, 146, 147; and (iii) a VH CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 142 and 148; and
(b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 195 and 198; (ii) a VL CDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 196 and 199; and (iii) a VL CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 197 and 200.
20. The isolated antibody of claim 1 , wherein the antibody (14C11) comprises a VH region comprising the amino acid sequence of SEQ ID NO: 15 and a VL region comprising the amino acid sequence of SEQ ID NO: 16.
21. The isolated antibody of claim 1 , wherein the antibody (26B9) comprises a VH region comprising the amino acid sequence of SEQ ID NO: 41 and a VL region comprising the amino acid sequence of SEQ ID NO: 42.
22. The isolated antibody of claim 1 , wherein the antibody (32A10) comprises a VH region comprising the amino acid sequence of SEQ ID NO: 11 and a VL region comprising the amino acid sequence of SEQ ID NO: 12.
23. The isolated antibody of claim 1 , wherein the antibody (30D8) comprises a VH region comprising the amino acid sequence of SEQ ID NO: 37 and a VL region comprising the amino acid sequence of SEQ ID NO: 38.
24. The isolated antibody of claim 1 , wherein the antibody (12B2) comprises a VH region comprising the amino acid sequence of SEQ ID NO: 30 and a VL region comprising the amino acid sequence of SEQ ID NO: 31.
25. The isolated antibody of claim 2 , wherein the antibody comprises:
a VH region comprising a selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 32, 34, 35, 37, 39, 41, 43, 44, 46, 48, and 50; and
a VL region comprising selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 36, 38, 40, 42, 45, 47, 49, and 51.